問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Surgery

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital (在職)

更新時間：2023-09-19

吳尚殷Wu, Shang-Yin
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • wusy.tw@gmail.com

Recruiting Trial

272Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳尚殷

List

478Cases

2018-03-01 - 2023-12-31

Phase III

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    Atezolizumab; Bevacizumab; Sorafenib

Participate Sites
5Sites

Terminated5Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2012-06-30 - 2019-06-30

Phase III

A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy

  • Condition/Disease

    Previously Undiagnosed Peripheral T-cell Lymphoma

  • Test Drug

    Pralatrexate

Participate Sites
8Sites

Terminated8Sites

2016-02-26 - 2018-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2020-07-01 - 2022-01-17

Phase I

A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors

  • Condition/Disease

    Malignant Solid Tumor

  • Test Drug

    SAR439459

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2021-09-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-09-01 - 2018-12-24

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-09-01 - 2018-01-04

Phase III

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen

  • Condition/Disease

    Metastatic Castration Resistant Prostate Cancer

  • Test Drug

    XRP6258

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

2011-09-29 - 2013-12-16

Phase II

A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MM-121(SAR256212)

Participate Sites
6Sites

Terminated6Sites

2015-01-01 - 2017-09-30

Phase III

An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck(SCCHN)

  • Condition/Disease

    Squamous Cell Cancer of the Head and Neck

  • Test Drug

    Nivolumab

Participate Sites
2Sites

Terminated2Sites

2015-07-01 - 2020-12-31

Phase II

Multicenter, open-label, single arm, Phase II study in advanced non-small cell lung cancer；Subtitle:A multicenter, open-label, single arm Phase II study to evaluate safety and efficacy of ONO-4538 in stage IIIB/IV or recurrent non-small cell lung cancer patients who are unsuited to radical radiotherapy and resistant to a platinum-base chemotherapeutic regimen.

  • Condition/Disease

    stage IIIB/IV or recurrent non-small cell lung cancer

  • Test Drug

    Opdivo®

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated8Sites

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

1 27 28 29 30 31 48
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB